New Report Covers Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape.
Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resistant prostate cancer is characterized by rising prostate specific antigen (PSA) with a low testosterone and is associated with poor prognosis. mHRPC arises when prostate cancer becomes non-responsive to hormone therapy and spreads to neighboring tissues or to other parts of the body such as the bones. Some of the most important predisposing factors for mHRPC include increasing age, environmental stress and genetic factors. Symptoms of mHRPC may include lethargy, paraplegia, bone pain, lower back or pelvic pain and weight loss. It may be controlled by hormonal therapy, radiation therapy or chemotherapy.
To access full report with TOC, please visit Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 6, 37, 20 and 19 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 4 and 1 molecules, respectively.Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology)
- The pipeline guide reviews pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AB Science SA AbbVie Inc Adamis Pharmaceuticals Corp Advaxis Inc Ambrx Inc Amgen Inc Aptevo Therapeutics Inc Armour Therapeutics Inc ArQule Inc Arrowhead Pharmaceuticals Inc Arvinas Inc Asana BioSciences LLC AstraZeneca Plc ATLAB Pharma SAS Aurigene Discovery Technologies Ltd Bavarian Nordic A/S BeiGene Ltd Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corp CellCentric Ltd Clovis Oncology Inc Corcept Therapeutics Inc Corvus Pharmaceuticals Inc Curevac AG DexTech Medical AB Eli Lilly and Company Endocyte Inc ESSA Pharma Inc F. Hoffmann-La Roche Ltd Gilead Sciences Inc Glactone Pharma AB GlaxoSmithKline Plc GTx Inc Ionis Pharmaceuticals Inc Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson MedImmune LLC Medivation Inc MEI Pharma Inc Millennium Pharmaceuticals Inc NewLink Genetics Corp Novartis AG Oncogenex Pharmaceuticals Inc Oncolytics Biotech Inc Ono Pharmaceutical Co Ltd Pfizer Inc Progenics Pharmaceuticals Inc Selexel Sotio as Supratek Pharma Inc Taiho Pharmaceutical Co Ltd Takeda Pharmaceutical Company Ltd Tesaro Inc Threshold Pharmaceuticals Inc Tiltan Pharma Ltd Tokai Pharmaceuticals Inc TRACON Pharmaceuticals Inc UbiVac LLC Viralytics Ltd Zenith Capital Corp
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 08:41
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home